ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 225.3 CHF | -1.50% |
|
-58.28% | -58.28% |
| Sales 2024 * | 42.97B 38.6B 3,399B | Sales 2025 * | 52.68B 47.32B 4,167B | Capitalization | 815B 732B 64,479B |
|---|---|---|---|---|---|
| Net income 2024 * | 11.93B 10.72B 944B | Net income 2025 * | 16.63B 14.94B 1,315B | EV / Sales 2024 * | 19.4 x |
| Net Debt 2024 * | 18.91B 16.99B 1,496B | Net Debt 2025 * | 16.06B 14.43B 1,270B | EV / Sales 2025 * | 15.8 x |
| P/E ratio 2024 * |
67.7
x | P/E ratio 2025 * |
48.5
x | Employees | 43,000 |
| Yield 2024 * |
0.57% | Yield 2025 * |
0.66% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | -1.50% | ||
| 1 week | -58.28% | ||
| Current month | -58.28% | ||
| 1 month | -58.28% | ||
| 3 months | -58.28% | ||
| 6 months | -58.28% | ||
| Current year | -58.28% |
1 year
225.31
540.00
3 years
210.33540.00
5 years
108.90540.00
10 years
54.85540.00
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 31/12/95 |
Ruth Gimeno
PSD | President | - | - |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 15/10/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 24/01/21 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 31/03/09 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 31/12/04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/06/24 | - | +-NaN% | 362 |
| 27/06/24 | - | +-NaN% | 461 |
| 26/06/24 | - | +-NaN% | 471 |
| 25/06/24 | - | +-NaN% | 933 |
| 24/06/24 | - | +-NaN% | 636 |
Delayed Quote London S.E., December 10, 2021 at 02:37 pm
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
08/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
905.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +44.05% | 641B | |
| -6.75% | 352B | |
| +13.56% | 314B | |
| +10.68% | 303B | |
| +16.57% | 242B | |
| +13.31% | 218B | |
| +8.48% | 168B | |
| -2.81% | 159B | |
| +0.20% | 120B |
- Stock Market
- Equities
- LLY Stock
- LEL Stock
